SG/PUT/ELI LILLY & CO/600/0.01/20.09.24 | Delayed Deutsche Boerse AG 19:20:23 01/07/2024 BST | ||
| 0.006 EUR | +50.00% |
|
| Current month | -85.71% | ||
| 1 month | -87.50% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
| Date | Price | Change |
|---|---|---|
| 01/07/24 | 0.006 | +50.00% |
| 28/06/24 | 0.004 | -33.33% |
| 27/06/24 | 0.006 | -14.29% |
| 26/06/24 | 0.007 | 0.00% |
| 25/06/24 | 0.007 | -12.50% |
Delayed Quote Deutsche Boerse AG
Last update July 01, 2024 at 07:20 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | PUT |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
Société Générale
|
| WKN | SW3ZJY |
| ISIN | DE000SW3ZJY3 |
| Date issued | 26/09/2023 |
| Strike | 600 $ |
| Maturity | 20/09/2024 (81 Days) |
| Parity | 100 : 1 |
| Emission price | 0.76 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.97 € |
|---|---|
| Lowest since issue | 0.003 € |
| Spread | 0.014 € |
| Spread % | 70.00% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
905.4
USD
Average target price
868.9
USD
Spread / Average Target
-4.03%
- Stock Market
- Warrants
- Warrant
